Actinogen Medical Released Alzheimer’s Disease Trial

Biotechnology company Actinogen Medical Limited’s (ASX: ACW) lead compound Xanamem has failed to demonstrate adequate efficacy in improving cognition in mild Alzheimer’s disease. In an update provided on 7 May 2019, the company announced the results of its Phase II Alzheimer’s Disease Trial in which it has informed that the primary and secondary endpoint measures had not demonstrated statistical differences between Xanamem 10mg and placebo.

Following the release of the results, the share price of the company crashed by 66.667% during the intraday trade (AEST 2:15 PM).

As per the initial data base of XanADu, 10 mg daily dose of Xanamem is safe and it is having the ability to effectively inhibit cortisol production. Further, the company believes that higher doses and longer treatment duration may be required to effectively demonstrate the drug’s potential to improve cognition in Alzheimer’s disease.

The company’s development program is going to provide greater insight into Xanamem’s safety and its activity on cortisol production in the brain help with the ongoing fight to find new effective therapies for the treatment of Alzheimer. It is expected that the initial results from these studies will be read out by the end of June and will provide important data to further inform and refine Xanamem’s ongoing clinical development program.

In its announcement, the Company has announced that it is extremely grateful to the patients and their carers who participated in XanADu, as their involvement has helped generate important clinical data on the treatment of Alzheimer’s disease with Xanamem and for the ongoing development of this drug.

As per the company’s CEO Dr Bill Ketelbe, XanADu results are certainly encouraging. While 10 mg Xanamem was proven to be a clinically effective dose in Alzheimer’s disease, the safety and pharmacodynamic effects observed demonstrate potential that higher doses and a longer treatment duration of Xanamem may be efficacious.

The Company is currently confident in the relationship between raised cortisol and cognitive impairment. As per the company’s announcement, the inhibition of cortisol production in the brain with Xanamem represents a compelling approach to treating cognitive impairment in Alzheimer’s and other neurological diseases, such as bipolar disorder and schizophrenia.

Alzheimer’s disease is currently a major health crisis with addressable market worth over US$7.5bn with unmet needs and potential upside. If the company is able to find a better treatment option for this disease it will be a very significant development for the company.

Now, let’s have a glance at the company’s stock performance and the return it has posted over the past few months. At the time of writing, i.e., on 7 May 2019 AEST 2:15 PM, the stock of the company was trading at a price of A$0.016, down 66.667% during the day’s trade with the market capitalisation of ~A$53.72 Mn. The stock has provided a year till date return of 6.67% & also posted returns of 4.35%, -17.24% & -11.11% over the past six months, three & one-month period respectively. It had a 52-week high price of $0.066 and touched 52 weeks low of $0.014, with an average volume of ~1,753,612.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   

Kalkine

Rated 4.3/5 based on 904 Reviews at Google My Business
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK